Entia Biosciences (OTCPK:ERGO) - Stock Price, News & Analysis

ERGO Stock Overview

Engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. More details

ERGO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($7K)

Latest financial reports are more than a year old

Shares are highly illiquid

Entia Biosciences, Inc. Competitors

LifeQuest World

OTCPK:LQWC

US$756.3k

Mace Security International

OTCPK:MACE

US$1.2m

Cyanotech

OTCPK:CYAN

US$2.5m

Nevis Brands

OTCPK:NEVI.F

US$2.7m

Price History & Performance

Summary of all time highs, changes and price drops for Entia Biosciences
Historical stock prices
Current Share Price	US$0.0002
52 Week High	US$0.0002
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-71.43%
5 Year Change	-98.99%
Change since IPO	-99.99%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ERGO	US Personal Products	US Market
7D	0%	5.5%	2.0%
1Y	n/a	-11.2%	32.4%

Return vs Industry: Insufficient data to determine how ERGO performed against the US Personal Products industry.

Return vs Market: Insufficient data to determine how ERGO performed against the US Market.

Price Volatility

Is ERGO's price volatile compared to industry and market?
ERGO volatility
ERGO Average Weekly Movement	n/a
Personal Products Industry Average Movement	8.2%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ERGO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ERGO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	n/a	Timothy Timmins	www.entiabio.com

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company’s portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant.

Entia Biosciences, Inc. Fundamentals Summary

How do Entia Biosciences's earnings and revenue compare to its market cap?
ERGO fundamental statistics
Market cap	US$6.81k
Earnings (TTM)	-US$1.40m
Revenue (TTM)	US$265.47k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ERGO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ERGO income statement (TTM)
Revenue	US$265.47k
Cost of Revenue	US$91.50k
Gross Profit	US$173.97k
Other Expenses	US$1.57m
Earnings	-US$1.40m

Last Reported Earnings

Dec 31, 2016

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ERGO perform over the long term?

See historical performance and comparison